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Abstract
The present study aims at developing a new, ultrafine particle-based efficient
antibiotic delivery system for the treatment of tuberculosis. The carrier material
to make the rifampicin (RIF)-loaded particles is a low molecular weight star-
shaped polymer produced from glucosamine (core building unit) and L-lactide
(GluN-LLA). Particles were made via electrohydrodynamic atomization.
Prolonged release (for up to 14 days) of RIF from these particles is reported.
Drug release data fits the Korsmeyer-Peppas equation, which suggests the
occurrence of a modified diffusion-controlled RIF release mechanism in vitro and
is also supported by differential scanning calorimetry and drug leaching tests.
Cytotoxicity tests on Mycobacterium smegmatis showed that antibiotic-free
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any significant anti-bacterial activity. The minimum inhibitory concentration and
minimum bactericidal concentration values obtained for RIF-loaded particles
showed 2- to 4-fold improvements in the anti-bacterial activity relative to the
free drug. Cytotoxicity tests on macrophages indicated that cell death correlates
with an increase of particle concentration but is not significantly affected by
material type or particle size. Confocal microscopy was used to track
internalization and localization of particles in the macrophages. The uptake of
GluN-LLA particles is higher than those of their PLA counterparts. In addition,
after phagocytosis, the GluN-LLA particles stayed in the cytoplasm and showed
favorable long-term drug release behavior, which facilitated the killing of
intracellular bacteria when compared to free RIF. The present studies suggest
that these drug carrier materials are potentially very attractive candidates for the
development of high-payload, sustained-release antibiotic/resorbable polymer
particle systems for treating bacterial lung infections.
Keywords: Microbiology, Pharmaceutical chemistry, Pharmaceutical science
1. Introduction
Tuberculosis (TB), a highly contagious disease caused by theMycobacterium tuber-
culosis (MTB), ranks as the second leading cause of death from an infectious disease
worldwide, and has affected 10 million people in 2017 according to the World
Health Organization (WHO). In the same year, 1.4 million people died from TB,
including 300,000 HIV-positive patients (Global tuberculosis report 2018. Geneva:
World Health Organization, 2018). MTB bacteria that access to a new host via
inhaled air can begin the replication process inside the alveolar macrophages
(AM) after 2e3 weeks of infection. Macrophages usually ingest and trap pathogens
in a phagosome, which is then subject to a series of fusion and fission events within
the endocytic pathways that end in phagosome-lysosome fusion. This process in
which phagosomes acquire the antimicrobial tools to eliminate the pathogen is
known as phagosome maturation. However,MTB can modulate pH-reducing events
in a maturing phagosome, which can result in a more basic phagolysomal pH, thus
facilitating bacteria survival, replication and dormancy of the disease (Gengenbacher
and Kaufmann, 2012; Welin and Lerm, 2012). The only treatment currently avail-
able for TB, chemotherapy, requires six months of an extensive multi-drug regimen
of rifampicin (RIF), isoniazid (INH), pyrazinamide (PYZ), and ethambutol (du Toit
et al., 2006). A serious drawback of chemotherapy is the limited bioavailability of
the dosed antibiotics in the target area, mainly because its first-pass metabolism de-
creases the amount of drug that gets into the blood stream. As a consequence, to
achieve therapeutic levels, large doses of drugs are normally needed, which in
turn increases the probability of side effects (Suarez et al., 2001). Hepatotoxicity,
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one the most common side effects of anti-TB drugs, generally leads to treatment
withdrawal and discontinuation (du Toit et al., 2006; Tostmann et al., 2008). This
long, intensive and commonly toxic treatment is one of the main causes for low pa-
tient compliance. Failure to adhere to the prescribed drug regime has resulted in the
significant emergence of multi-drug resistant TB (MDR-TB) strains of MTB. Treat-
ment of MDR-TB takes longer than conventional TB treatment modalities (WHO
recommends 20 months), and requires more expensive and toxic drugs with lower
success rates (Cohen et al., 2003; Rakotonirina et al., 2009; Y. Zhang and Yew,
2009). These difficulties are the main driver behind new research aimed at exploring
new drug administration concepts.
An alternative strategy to current treatment approaches is to encapsulate anti-TB
drugs in nano- or microparticles (MP) made from biodegradable polymers (Hirota
et al., 2010; Makino et al., 2004; Mehanna et al., 2014; Ohashi et al., 2009; Vyas
et al., 2004). For instance, a very effective particulate treatment should target and
undergo endocytosis by AM, and deliver anti-TB drugs where MTB is harboring
via phagosome maturation arresting (Mehanna et al., 2014; Vyas et al., 2004).
Among all the administration routes, inhalation has the inherent benefit of chiefly
by-passing first-pass metabolism, thereby allowing elevated local concentrations
of the drug where it is most needed, and without requiring high drug concentrations
in circulation. This, in turn, reduces systemic toxicity risks (Ranjita et al., 2011).
Since alveolar macrophages are one of the first lines of defense against entry of
external particles including microbial invasion, AM targeting is generally accom-
plished even without any specific tailoring of the particles (Fenaroli et al., 2014).
Various drug carriers derived or purified from natural sources such as chitosan
(Rajan and Raj, 2012), alginate (Ahmad et al., 2007), gelatin (Manca et al.,
2013), and synthetic encapsulants, such as poly(lactide-co-glycolide) (PLGA),
poly-D,L-lactide (PDLLA), and polyanhydrides have been used in anti-TB drug
encapsulation. RIF is one of the first-line antibiotics being used in TB treatments
and is usually employed when investigating new particulate systems. A review of
the recent literature on RIF controlled release systems reveals that the most popular
proposed drug carriers still belong to PLGA family (Ain et al., 2002; Doan et al.,
2011; Doan and Olivier, 2009; Dutt and Khuller, 2001; Hirota et al., 2010; Hong
et al., 2008; Ito and Makino, 2004; Makadia and Siegel, 2011; Makino et al.,
2004; Pandey et al., 2003; Sharma et al., 2004; Suarez et al., 2001; Tomoda et al.,
2005; Yoshida et al., 2006). We have found very few studies reporting on the prep-
aration of MP made from PLA polymers loaded with RIF (Bain et al., 1999;
Celikkaya et al., 1996; Coowanitwong et al., 2008; Patomchaiviwat et al., 2008).
The present study aims at developing a RIF loaded-particulate system that delivers
the therapeutic in a sustain manner over a long period of time as an alternative treat-
ment of TB. In this work, in vitro release of RIF, from submicron particles (SMP)
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and MP from a linear LMW and HMW L-lactide, and branched L-lactide grafted
glucosamine (GluN-LLA) oligomers produced by electrohydrodynamic atomization
(EHDA) was investigated. The custom-made, highly branched biocompatible olig-
omer, GluN-LLA (Skotak and Larsen, 2010), was processed into SMP and MP, re-
sulting in nearly monodisperse particle size distribution (PSD) systems. For drug
delivery applications, three of the most desirable traits of these GluN-LLA oligomers
are their high solubility in low toxicity solvents, their tunable hydrophobicity-
hydrophilicity balance via control of the length of the lactide substituents, and their
LMWs. Cytotoxicity effects of L-lactide, and GluN-LLA base particles on macro-
phages; and the bactericidal activity of encapsulated and free RIF toward the chosen
model microorganism, Mycobacterium smegmatis (M. smegmatis), were evaluated.
M. smegmatis is a non-pathogenic and fast-growing species (generation times of
3e4 hours) that shares 2,000 homologs withMTB, which makes this microorganism
the most accepted model to study MTB (Reyrat and Kahn, 2001). The effects pro-
duced by the polymeric matrix were evidenced by the minimum inhibitory concen-
tration (MIC) and minimum bactericidal concentration (MBC) values. Confocal
microscopy was used to determine the internalization and intracellular location of
L-lactide and GluN-LLA based particles containing RIF into macrophages. Finally,
the intracellular killing of M. Smegmatis in AM showed that the particles are able to
maintain a sustained release of RIF into the cells with release rates affecting the bac-
teria death rate, further pointing to the potential of GluN-LLA as a possible new drug
carrier for the treatment of TB.
2. Materials and methods
2.1. Materials
Rifampicin (RIF, >97% HPLC), D-(þ)-Glucosamine hydrochloride (GluN-HCl,
min. 99%), ethyl acetate (EA, 99.8%) and methanesulfonic acid (MSA, >99.5%)
were from Sigma-Aldrich, and ethanol (>99.5%) was received from McCormick
Distilling Co., Inc. High molecular weight poly-L-lactide (HMW PLA, Nature-
Works Ingeo 8302D) with Mn ¼ 123 kDa and polydispersity (PDI) 1.75 (GPC)
was purchased from Jamplast, Inc. The L-lactide (LLA, 98%, Alfa) was re-
crystallized from toluene, vacuum-filtered in an argon atmosphere, vacuum-dried,
and stored in a desiccator. All the other chemicals and reagents were purchased
from Sigma-Aldrich except where indicated. The low molecular weight poly-L-
lactide and GluN-LLA polymer synthesis is described in the following section.
2.2. Polymer synthesis
Low molecular weight poly-L-lactide (LMW PLA, Mn ¼ 2,500 Da, PDI ¼ 1.4
(GPC)) was synthesized according to a procedure published elsewhere (Bourissou
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et al., 2005). The GluN-LLA (Mn ¼ 3,100 Da (NMR), PDI ¼ 1.47 (GPC)) with
average side-chain length of 11 monomeric L-lactide units, was prepared according
to a procedure reported earlier (Skotak and Larsen, 2010; Skotak et al., 2008).
Briefly, ten mL of MSA were transferred into a 50 mL flask under argon atmosphere
and placed in an oil bath kept at 40 C. Subsequently, 3.5 mmol of GluN-HCl was
added and stirred until homogenization. Then, the L-lactide was added to the reac-
tion mixture, and the flask was flushed with argon for 10 minutes to remove the liber-
ated gaseous HCl. Polymerization of L-lactide occurred for four hours, and the
reacting mixture was afterwards quenched with an acid-base neutralization solution,
as described elsewhere (Skotak et al., 2008). Vacuum filtration and vacuum drying
overnight at the ambient temperature were carried out to isolate and dry the product.
Samples were stored in a desiccator until use.
2.3. Particle preparation and characterization
2.3.1. Particle preparation
SMP were prepared from a 5% (w/v) GluN-LLA or LMW PLA, while MP were pre-
pared from a 20% (w/v) GluN-LLA or 1% (w/v) HMW PLA. The preparation of
polymeric precursor solutions was done by dissolving the corresponding polymers
into EA. These solutions were processed into four different sets of particles using
a conventional single-nozzle EHDA setup. The resulting particles were labeled as
SMP-GluN-LLA, SMP-LLA and MP-GluN-LLA, MP-LLA, respectively. For the
preparation of RIF-loaded particles, three different drug loadings were used: 10,
20 and 50 wt%, which correspond to RIF-to-polymer mass ratios of 1:10, 1:5 and
1:1, respectively; the 1:5 and 1:1 ratios were the most studied in the present contri-
bution. The precursor solution was loaded into a Hamilton series 1000 gastight sy-
ringe (model 1001, 1 mL), with a 19 gauge blunt needle attached (to serve as the
EHDA nozzle). Subsequently, the syringe was mounted on a digital syringe pump
(Cole-Parmer 74900-00, Vernon Hills, IL). Voltage differences in the range of
5e15 kV, (Gamma High Voltage Research ES30P-5W/PRG, Ormond Beach, FL)
and a nozzle-to-collector distance of 10 cm were used in the course of a typical
experiment. Various flow rates in the range of 0.2e0.5 mL/h were tested to find
optimal processing conditions in order to make particles with narrow diameter dis-
tributions. The particles were deposited onto an aluminum foil collector tightly
wrapped around 15 cm OD circular copper disk. The temperature and relative hu-
midity during the collection of particles were approximately 24 C and 45%, respec-
tively. The collection time was limited to 10 minutes (optimization phase) or
extended up to a few days to collect amounts of particles suitable for further studies.
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2.3.2. Size and morphology
Particle size and morphology were assessed via scanning electron microscopy
(SEM), using a Hitachi S-3000N microscope with an accelerating voltage of 15
kV and working distance of approximately 13 mm. Coating with metallic gold for
2 minutes before SEM characterization was used to enhance the contrast of non-
conducting samples. The electrical current inside the chamber of the Technics Hum-
mer II sputter coater was kept constant (10 mA). Statistical analysis of particle size
measurements from SEM images was performed on sets of at least 250 counts within
each specimen.
2.3.3. Drug encapsulation efficiency
Approximately 40e50 mg of RIF loaded particles were treated with 5 mL of anhy-
drous ethanol for 10 minutes (L-lactide polymers are not soluble in this solvent, RIF
solubility in ethanol is roughly 10 mg/mL). The suspension was then centrifuged, the
supernatant transferred to a 30 mL beaker and subsequently diluted to 15 mL. UV-
Vis spectra of RIF in ethanol were recorded in the 250e550 nm range, and concen-
trations were calculated based on the absorption peak at 306 nm. The drug content
entrapped within the particles was analyzed with 1H NMR spectroscopy, using
deuterated chloroform (CDCl3, 99.8 atom % D, Sigma-Aldrich) as solvent. Charac-
teristic signals of methyl groups of RIF (1.04, 0.89 and 0.62 ppm) and polymer
matrices (1.60 ppm) were compared and used to calculate the drug-to-polymer ratio.
Particles that were not treated with ethanol were used as reference.
2.3.4. Particle degradation
Polymer degradation studies were performed using a modified PBS solution: water
was replaced with deuterated water to facilitate NMR analysis of the released L-lac-
tic acid. First, the pH of the PBS stock solution was adjusted to 7.4 with 1 M HCl,
then water was evaporated and the remaining solid was dried under vacuum. Then,
the dry PBS powder was dissolved in deuterated water (D2O, 99.8 atom % D, Cam-
bridge Isotope Laboratories) for further use. Solid polymeric particles (50 mg) were
dispersed in 5.0 mL of deuterated PBS and the suspension was kept in the dark at 37
C while shaking it. For NMR analysis, 0.5 mL aliquots were drawn every 24 hours
and 1H NMR spectra were recorded on a Bruker Avance 500 NMR spectrometer at
500.13 MHz to track the release of L-lactic acid. Following analysis, samples were
poured back into their respective particle suspensions. These studies were done in
triplicate for all tested particle types, and for 14 consecutive days.
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2.3.5. Thermal properties of RIF loaded particles
Differential Scanning Calorimetry (DSC) runs were performed on Q100 machine
(TA Instruments, New Castle, USA), calibrated for temperature and heat flow using
indium (melting point 156.6 C and DHm, 28.45 J/g, respectively). Two analytical
runs (to confirm repeatability) were performed on each sample at a heating rate of 10
C/min., by ramping temperature from 0 to 300 C, and the sample compartment was
flushed with dry nitrogen flowing at 25 mL/min. An empty hermetic Al pan was used
as a reference.
2.3.6. Drug release studies
Drug release studies were performed under “perfect sink” conditions (Ritger and
Peppas, 1987). Briefly, a mass equal to 50 mg of RIF-loaded particles was dispersed
in 5 mL of phosphate buffered saline (PBS) (n ¼ 3) (pH ¼ 7.4) supplemented with
0.02% of ascorbic acid as an antioxidant (Makino et al., 2004), the vials were kept in
a thermostat/shaker at 37.0  0.1 C in the dark. Samples of 200 ml were extracted
from each vial every hour for the first 8 hours, and then every 24 hours, the total vol-
ume was kept constant by replacing the extracted sample volume with 200 ml of fresh
PBS. RIF content was measured with a Beckman DU-640 spectrophotometer in the
250e550 nm wavelength range. In the past, the RIF release kinetics has been eval-
uated at the isosbestic point of the drug, and through its quinone degradation product
(330 nm) (Bain et al., 1999; Hong et al., 2008). Absorbance values at 310 nm were
used to calculate the concentration of RIF in the absence of drug oxidation, which
was prevented by addition of ascorbic acid and a lack of sample exposure to light.
2.4. Data fitting and statistical analysis
Data fitting of temporal RIF release profiles was performed using non-linear curve
fitting built-in module of the Origin 9.0 software. Typically, 60% of the data points
were used and fitted to the Korsmeyer-Peppas equation (as required by the model)
(Ritger and Peppas, 1987). Statistical evaluation was performed using ANOVA
test with p-values below 0.05 and 0.01 considered as significant.
2.5. Evaluation of particle effects on bacteria
2.5.1. Bacterial strain
M. smegmatisATCC 607 was purchased fromHardy Diagnostics (Santa Maria, CA),
and cultured at 37 C with shaking (150 rpm) in Difco Middlebrook 7H9 (BD Diag-
nostics, Sparks, MD) medium supplemented with 0.5% (v/v) glycerol, 0.05% Tween
80 to prevent clumping, 10 mg/mL cycloheximide to prevent fungal contamination,
50 mg/mL carbenicillin to prevent other bacterial contamination, and ADS (0.5%
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bovine serum albumin, 0.01 M dextrose and 0.015 M NaCl). For each experiment, a
fresh overnight culture was prepared with a terminal OD600 reading less than 0.4.
2.5.2. Particle toxicity on M. smegmatis
1 Three million colony forming units (cfu) of freshly prepared mycobacteria were
inoculated in 10 mL of 7H9 complete medium for 1 hour at 37 C before the addition
of different amounts of particles (0, 300, 600 and 1,200 mg/mL). The cultures were
maintained in the oven at 37 C with continuous shaking at 150 rpm for 24 hours,
and then 10 mL of culture was inoculated onto 7H10 agar plates (7H10 agar supple-
mented with the same ingredients as 7H9 complete medium without Tween 80)
without spreading out and incubated at 37 C for 3 days to produce visible colonies.
Mycobacteria in 7H9 complete medium without particles were considered the parti-
cle toxicity control. Pictures of agar plates were taken with a digital camera (24 MP
resolution), areas of the colonies formed were quantified by ImageJ software.
2.5.3. Determination of minimum inhibitory concentration
(MIC)
The MIC of free RIF and RIF loaded particles forM. smegmatis were determined by
standard macrobroth dilution techniques recommended by the Clinical and Labora-
tory Standard Institute (CLSI). Briefly, a series of dilutions of free (0, 1, 2, 4, 8, 16,
32, 64, 128, 256, 512 mg/mL) and RIF encapsulated particles (according to 1:5 RIF-
to-polymer mass ratio, 0, 5, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 mg of loaded
particles/mL, and 1:1 ratio 0, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024 mg of loaded
particles/mL) in 7H9 medium were prepared. Bacterial suspensions were then added
to each tube to make final inocula of 3  105 cfu/mL; 10 mL of culture from each
tube was taken and then placed onto a 7H10 agar plate without spreading it out.
The plates were cultured at 37 C for 3 days before the colonies were analysed.
The lowest concentrations of antibiotic formulations that inhibited the visible bacte-
rial growth after 24 hours were assigned as MIC using McFarland turbidity standard
value of 0.5 as reference. Minimum bactericidal concentration (MBC) was defined
as the minimal concentration which kills at least 99.9% of bacterial population
compared with those in control vials.
2.6. Evaluation of particle loading effects on macrophages
2.6.1. Cell line
Mouse macrophage cell line J774A.1 was purchased from ATCC (Manassas, VA).
The cells were grown in Dulbecco’s modified eagle’s medium (DMEM, Global Cell
Solutions, Charlottesville, VA) supplemented with 10% fetal bovine serum (FBS,
PAA Lab, Westborough, MA) and antibiotics containing 100 units/mL penicillin,
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100 mg/mL streptomycin and 250 ng/mL amphotericin B (Lonza, Walkersville, MD)
at 37 C and 5% CO2 in a humidified incubator.
2.6.2. Cytotoxicity of particles on macrophage cells
WST-8 assay (Dojindo Molecular Technologies, Inc.) was performed per manufac-
turer’s instructions. In brief, J774A.1 macrophages were seeded in 96-well plates at a
density of 1 104 cells/well, and incubated with SMP-GluN-LLA, MP-GluN-LLA,
SMP-LLA, and MP-LLA (0 (control), 30, 60, 120 and 240 mg/mL) for 3 days at 37
C in humidified atmosphere (90% humidity), 5% CO2. WST-8 reagent solution (10
mL) was added to each well without changing medium, and the plates were incubated
for 1 hour prior to OD450 measurement with a BioTek Elx800 microplate reader.
Viability of J774A.1 cells was determined from the absorbance of WST-8 in the
cell suspension and sample without particle exposure is considered as corresponding
to 100% viability.
2.6.3. Particle uptake, and intracellular compartmentalization by
confocal microscopy
To determine the internalization of particles into macrophages, 4  105 cells were
seeded in 35mm glass bottom dishes (MatTek, Ashland, MA) and incubated for
48 hours with 120 mg/mL particles labelled with 1% poly-caprolactone-fluorescein
conjugate (PCL-fluorescein, Advanced Polymer Inc, Carlstadt, NJ). For these exper-
iments, 1% w/w PCL-fluorescein/polymer was added to the GluN-LLA or PLA so-
lution before particle fabrication. Subsequently, the cells were stained with 100 nM
of MitoTracker or LysoTracker (Invitrogen, Carlsbad, CA) in serum-free and
phenol red-free DMEM for 10 minutes. CellMask plasma membrane staining (In-
vitrogen) was also performed to confirm the particle internalization. Finally, cells
were washed and visualized with a confocal microscope (Olympus FV500-IX 81).
2.6.4. Intracellular killing of M. smegmatis
To examine the effects of RIF loaded particles on killing efficiency ofM. smegmatis
in macrophages, 105 cells per well were seeded in 24-well plates and allowed to
grow for 24 hours before infection. After washing with antibiotics-free medium
twice, 20 multiplicity of infection (MOI: ratio of bacteria/cells) of fresh growing
M. smegmatis was used to infect the cells for 1 hour and then extracellular bacteria
were killed by the addition of gentamicin (20 mg/mL). Free (30 mg/mL), or RIF
loaded particles (60 mg/mL, according to 1:1 RIF-to-polymer mass ratio), was
then loaded into the cell culture with growing medium without antibiotics. After
the incubation period, cells were washed and lysed with water and intracellular sur-
vival was estimated by plating serially diluted cultures on 7H10 plates. Pictures of
agar plates were taken with a digital camera (24 MP resolution) after 3 days, and
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the colonies were counted using ImageJ software. To determine the relative popula-
tion of surviving cells after infection, macrophages were stained with the Live/Dead
viability kit (Invitrogen, 4 mM EthD-1 and 2 mM Calcein AM). After 10 minutes of
incubation with dyes, cells were examined with VWR Vistavision Inverted Epifluor-
escence microscope attached to a LissView Imaging system. Cells were then
counted using ImageJ software.
3. Results and discussion
3.1. Particle fabrication: optimization of processing conditions
Due to the fact that ultimately, fully biocompatible drug delivery systems are
desired, particles were prepared using (the relatively less toxic) ethyl acetate solvent
to dissolve GluN-LLA and PLA polymers. Particle size and morphology was char-
acterized by the processing of SEM images with Gimp 2.8 software. We determined
that the simplest way to achieve particle size control was by varying polymer con-
centration. Preliminary tests using the GluN-LLA oligomer were performed at three
different weight/volume percentages: 5, 10 and 15 (Fig. 1), while keeping flow rate
in all cases at 0.5 mL/h. It is clear that at 5 kV, average particle diameters (PDs) in-
crease (0.79, 0.91 and 2.62 mm) with increasing polymer concentration, and the PSD
were relatively broad in all samples (standard deviation: 0.94, 1.01, 1.88, respec-
tively). Increasing the processing voltage to 10 kV resulted in decreased average
PDs (Fig. 1B).
Fig. 1. Control over particle size is achieved by varying the concentration of GluN-LLA. Samples were
solubilized in ethyl acetate and processed at 0.5 mL/h flow rate and voltages of: A) 5 kV, B) 10 kV. With
increasing voltage, the average particle size decreases while particle diameter distribution becomes nar-
rower. Increasing polymer concentration increases the average particle size (◄). Box range: 10e90%,
whisker range: 5e95%, () 1e99%, () min. and max. values of particle diameter within investigated
population. Inset: bimodal particle size distribution for sample prepared using 5 % w/v GluN-LLA con-
centration. Particle diameter means are significantly different (p < 0.01) at 5kV and 10kV.
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The polymer concentration was then fixed at 5 %, and the flow rate was varied from
0.2 to 0.5 mL/h, in 0.1 mL/h increments (Fig. 2). As it turned out, samples processed
at 5 kV displayed a bimodal PSD, with 80% of particles being in the submicron re-
gion (Fig. 1, inset). This usually is indicative of either the presence of more than one
mode of electrified jet breakup, or the occurrence of a “satellite” droplet formation
mechanism (Wilhelm et al., 2003). At 10 kV, a practical PSD unimodality was
achieved at a flow rate of 0.3 mL/h, with only 3% of population consisting of
supra-micron-sized particles. However, a tradeoff between unimodality and PD (if
the general goal of using EHDA is indeed making ultrafine particles) becomes
apparent, as the former comes at the expense of making larger particles (Fig. 2B).
Since in this work our objective was to focus on drug release from well-defined
PSDs, we preferred to process our samples at a flow rate of 0.3 mL/h and voltage
of 10 kV. Interestingly, increasing the voltage to 15 kV did not lead to smaller
PDs. We attribute this effect to a multi-jetting mode being in operation exclusively
at 10 kV. The single-jet mode was observed at 5 and 15 kV. The latter leads typically
to larger particles relative to cases in which more than one electrified liquid jet is
ejected from the Taylor cone. This same trend was also observed during our attempts
to optimize the MP design from GluN-LLA and HMW PLA, which suggests that
this may be a characteristic of the solvent system, rather than a solute effect.
Fig. 2. The effect of processing conditions, flow rate and voltage (A: 5 kV, B: 10 kV) on particle size and
distribution. Particles were prepared using a 5% (w/v) solution of GluN-LLA in ethyl acetate. Processing
at 5 kV resulted in a bimodal particle size distribution with 80% of the population in sub-micrometer
range. Box range: 10e90%, whisker range: 5e95%, () 1e99%, () min. and max. values of particle
diameter within investigated population Box plots present submicron populations exclusively. Particle
diameter means are significantly different (p < 0.01) at 5kV and 10kV.
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3.2. Fabrication of pure and RIF-loaded submicron- and micron-
sized particles
Electrospray, one of the two popular EHDA techniques, was used to develop one-
step methods to prepare four sets of particles composed of two different polymeric
materials, namely GluN-LLA and PLA. These groups of particles were labeled as
SMP-GluN-LLA, MP-GluN-LLA, SMP-LLA, and MP-LLA (Table 1). SMP based
on LMW PLA (SMP-LLA) were prepared from their 5% (w/v) solutions in EA at the
chosen processing conditions (0.3 mL/h, 10 kV, 10 cm). In order to guarantee com-
plete polymer dissolution and avoid precipitation, the solution needed to remain at
Table 1. Polymers used in RIF release studies. Type, molecular weight (Mn),
processing solution concentration and diameters (average SD) of pure and RIF-




Concentration, % Particle diameter, mm
Particle type Pure polymer 1:5a 1:1a
GluN-LLA 3,100 5.0 SMP-GluN-
LLA
0.50  0.30 0.57  0.45 0.90  0.70
20.0b MP-GluN-LLA 2.10  0.60 e e
LMW PLA 2,500 5.0 SMP-LLA 0.37  0.30 0.87  0.80 1.22  1.0
HMW PLA 123,000 1.0 MP-LLA 2.90  0.90 e e
a) RIF-to-polymer mass ratio used to prepare particles, i.e. 20% and 50% by weight, respectively.
b) Flow rate 0.5 mL/h was used.
Fig. 3. MP-GluN-LLA (A) and MP-LLA (B) were prepared at discrete voltages as indicated in respec-
tive plots. There are statistically significant differences between all populations within the subsets A and
B (p < 0.01). Insets show the difference in particle morphology between low and high molecular weight
polymers prepared at 10 kV. Spherical MP-GluN-LLA resulted from processing 20% (w/v) GluN-LLA
(A). MP-LLA with toroidal shape were obtained by using 1% (w/v) HMW PLA (B). Average particle
size (◄), box range: 10e90%, whisker range: 5e95%, () 1e99%, () min. and max. values of particle
diameter within investigated population.
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40 C during processing. For the preparation of SMP-GluN-LLA, a 5% (w/v) GluN-
LLA in EA solution was used and processed under the same EHDA conditions. The
SMP-LLA presented an average particle diameter slightly smaller than those of their
branched counterparts (Table 1). For the preparation of MP-LLA, a concentration of
1% (w/v) of HMWPLA was found to be very close to the polymer’s solubility, and
that value was selected for sample production under the same processing conditions.
MP-GluN-LLA are obtained with 20% (w/v) of GluN-LLA in EA when processed at
0.5 mL/h, 10 kV, and a 10 cm electrode-to-electrode distance.
Fig. 3 shows how voltage affects the PD and PSD of GluN-LLA and PLA MP
(Fig. 3A and B, respectively). In this case, a voltage of 10 kV and an emitter-
collector distance of 10 cm produce the desired PD and narrow PSD for MP-LLA
and MP-GluN-LLA. While MP-GluN-LLA are virtually spherical, MP-LLA shows
a toroidal shape which, based on our experience, is indicative of rapid solvent evap-
oration, that in turn leads to imploded “doughnut”- or “raisin”-shaped particles
(Fig. 3, insets). The size and shape of the particles are crucial factors for delivery
into the pulmonary airways: particles with aerodynamic diameters between 1-5
mm are preferred (Mohamed & Van Der Walle, 2008; Mortensen et al., 2014).
MP with sizes larger than 5 mm are usually deposited in the oral cavity, and SMP
particles smaller than <0.5 mm move by Brownian motion and settle slowly. NPs
(<100 nm) are not likely to deposit effectively in the pulmonary airways because
they are exhaled before deposition (Mortensen et al., 2014). In this work, two size
ranges were thus intentionally made: SMP between 0.5 to 0.8 mm and MP between
2 to 3 mm (Table 1). These nearly monodisperse particles were prepared easily, and
without using any EHDA apparatus modification. The PD ranges achieved would
thus fall within the targeted size ranges for our long-term objective ie., using them
for inhalation as mode of drug administration.
To evaluate effects of drug loading on particle morphology and PSD, we performed
tests for SMP-GluN-LLA and SMP-LLA at two drug loadings, namely 20 and 50 wt
%, which correspond to RIF-to-polymer mass ratios of 1:5 and 1:1, respectively
(Figs. 4 and 5). At 20 wt% loading, the broadening of the PSD in this sample (5/
1, SMP-LLA) and that of the control differ in a statistically significant manner (*p
< 0.01), but this was not observed in the SMP-GluN-LLA sample (Fig. 3A and
B). A loading of 50 wt% (5/5) resulted in further PD increases, and in broadening
of the PSDs, which could be a consequence of the higher concentration of polymer
in the precursor solution. Differences in the PDs of SMP-LLA and SMP-GluN-LLA
at a 5/5 polymer to RIF ratio were found to be statistically significant at **p < 0.01.
We stress the fact that very high drug loadings and slow release profiles are two
extremely desirable traits, and this is exactly the reason why we chose to focus on
such high RIF payloads. An increase in general surface irregularities has previously
been observed (e.g., particles with wrinkled surfaces) in PLGA MP with increasing
RIF loading (Hong et al., 2008). We note however, that this is not indicative of phase
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separation: in our case, separate RIF crystals were never observed by SEM (Fig. 4C,
and F).
3.3. Drug encapsulation efficiency
The RIF loading efficiency measured by the EtOH leaching test indicates that the
GluN-LLA polymer is superior to its linear homopolymer counterparts irrespective
of MW and characteristic dimensions of the particles (Table 2). These results corre-
spond to the amount of RIF retained within the particles at the end of the initial 8-
hour period when PBS was used. The entrapment efficiency in the MP is comparable
to those of RIF-loaded PLGA MP prepared via the oil-in-water emulsification
method (57e78% for PLGAs with MWs 10 and 20 kDa) (Makino et al., 2004).
They are also well above those reported with RIF-loaded HMWPLA MP prepared
via the supercritical anti-solvent method performed at comparable drug-to-
Fig. 4. SEM images illustrating the gradually changing morphology of polymeric submicron particles
made of low molecular weight polymers as RIF content is increased: SMP- GluN-LLA (top row) and
SMP-LLA (bottom row). Pure polymeric particles (A, D) and with RIF-to-polymer mass ratios of 1:5
(B, E) and 1:1 (C, F) are presented. The scale bar (10 mm) is the same for all images, except E (25 mm).
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Fig. 5. The effect of RIF loading expressed as polymer-to-RIF mass ratio, average diameter and particle
size distribution. Two low molecular weight polymers were tested: A) SMP-GluN-LLA made with
branched GluN-LLA, and B) SMP-LLA made with linear LMW PLA. Particles were prepared at a
flow rate of 0.3 mL/h and voltage of 10 kV. There are statistically significant differences between
SMP-GluN-LLA and SMP-LLA (5/5 polymer to RIF ratio) when compared with their controls, panels
A and B (**p < 0.01). At the 5/1 ratio, only the SMP-LLA were statistically significant different
when compared with its control (*p < 0.01). Average particle size (◄), box range: 10e90%, whisker
range: 5e95%, () 1e99%, () min. and max. values of particle diameter within investigated
population.
Table 2. Encapsulation efficiency and kinetic parameters of RIF release from L-











GluN-LLA 1: 5 SMP-GluN-
LLA
56.0  0.1 97.5 0.13 0.29 0.90
1:10 SMP-GluN-
LLA
e 96.6 0.15 0.28 0.90
LMW PLA 1: 5 SMP-LLA 15.0  0.2 98.3 0.71 0.14 0.99
GluN-LLA 1: 5 MP-GluN-LLA 71.0  1.7 93.1 0.14 0.33 0.95
1: 10 MP-GluN-LLA e 98.1 0.22 0.25 0.93
HMW PLA 1: 5 MP-LLA 52.0  0.9 99.0 0.10 0.54 0.98
a) The drug was extracted with pure ethanol for 10 minutes and the remaining solid was analyzed via 1H
NMR.
b) Results based on initial (theoretical) and cumulative drug loading (calculated from in vitro release
experiments).
c)Mt/MN ¼ ktn, where k is the constant incorporating characteristics of the macromolecular network sys-
tem and the drug, n is the exponent describing release mechanism, Mt/MN is the fraction of the drug
released at time t.
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polymer ratios (40e50%) (Patomchaiviwat et al., 2008). In general, the encapsula-
tion efficiency calculated from cumulative release curves well exceeded 90% for
all tested LMW systems (Table 2) but is extremely low for HMWPLA. This is an
expected result, as the low degradation rates of this class of polymers often results
in permanent drug entrapment inside polymer network (Zeng et al., 2003).
3.4. Particle degradation
The degradation studies performed under identical conditions as those from drug
release measurements revealed that L-lactic acid (LLA) release is proportional to
the available contact surface between polymeric particles and the solution (Fig. 6).
All tested polymers are hydroxyl-terminated and on a molecular level, the degrada-
tion mechanism for these polymers is end chain scission (van Nostrum et al., 2004).
Both types of SMP exhibited similar degradation curves, but after two weeks the
LLA concentration was higher for SMP-GluN-LLA, 8.2  103 mM, than the 4.0
 103 mM observed with SMP-LLA. Overall, after 14 days, material loss due to
degradation of the polymer matrix accounts for only 5% of the initial particulate
mass in vitro, and thus has negligible effect on the RIF release mechanism.
3.5. Thermal properties: impact on drug release kinetics
1 The DSC measurements revealed that the RIF used in our studies is the stable type
I form (a single, sharp exothermic signal, peaking at 253 C is the only feature in its
Fig. 6. Semi-log plot of degradation of submicron- (open symbols) and micron-sized particles (filled
symbols) prepared using linear (left panel) and branched (right panel) L-lactide based polymers. The
release of L-lactic acid was tracked via 1H NMR spectroscopy. Data represent means  SE (n ¼ 3).
16 https://doi.org/10.1016/j.heliyon.2019.e01539
2405-8440/ 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Article Nowe01539
thermograms) (S. Agrawal, Ashokraj, Bharatam, Pillai and Panchagnula, 2004). The
glass transition temperatures (Tgs) for RIF-loaded SMP and MP prepared with
GluN-LLA increased by 8e10 C when compared to that of the pure polymer
(Fig. 7, thermograms b, c and d) (Skotak and Larsen, 2010). This is indicative of
enhanced drug-polymer molecular interactions, i.e. RIF likely binds to terminal hy-
droxyl groups of GluN-LLA chains, thereby increasing its “effective molecular
weight”, as evidenced by augmented Tg values. On the other hand, introduction
of RIF is less likely to be responsible for the observed differences in thermal prop-
erties between pure and drug-loaded LMW PLA SMP. The as-prepared material is
highly crystalline and there is no obvious characteristic glass transition inflection
point seen in its thermogram (Fig. 7f). However, rapid solvent evaporation during
processing results in semi-crystalline features: Tg (46 C) and an exothermic “cold
crystallization” peak at 77 C were followed by an endothermic melting peak at
133 C. If the drug occupies exclusively the limited available amorphous polymer
regions and molecular interactions are thus very weak or absent; then it will be
rapidly released upon contact with the PBS solution (Fig. 6) or ethanol (Table 2).
2 Differences in molecular architecture have a pronounced effect on the thermal
properties of these polymers: while GluN-LLA is purely amorphous as evidenced
by the previously reported DSC results, Tg ¼ 43.7  1.3 C and the absence of
the melting peak of the crystalline phase (Skotak and Larsen, 2010), the LWM
PLA possesses semi-crystalline characteristics (Fig. 7f) (Bouapao and Tsuji,
2009). The DSC results suggest that chain length is a decisive crystallinity control
factor for oligo-L-lactides, and transition from an amorphous to a semi-crystalline
material takes place for monomer numbers higher than 10e12. In view of our re-
sults, the advantages of using branched over linear molecular architectures for
Fig. 7. DSC thermograms. a) RIF, b) as prepared GluN-LLA polymer, c) RIF loaded SMP-GluN-LLA,
d) RIF loaded MP-GluN-LLA, e) RIF loaded SMP-LLA f) as prepared LMWPLA. For samples c-e the
RIF-to-polymer ratio was 1:5.
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RIF delivery applications are apparent. The fine-tuning of the polymeric matrix crys-
tallinity (a strategy that is sometimes used as an important drug release control fac-
tor) requires detailed knowledge of its thermal properties, and often demands the use
of an additional post-processing step (Jeong et al., 2003). In matrices with reduced
crystallinity, such as the purely amorphous GluN-LLA, drug-polymer interactions
are enhanced. This, in turn, leads to efficient dispersion of the drug within the poly-
mer matrix, making these systems excellent candidates for applications requiring
slow release of the drug (Freiberg and Zhu, 2004). Such systems would indeed be
well suited for TB treatment: a typical TB treatment lasts 6 months, and with daily
drug doses (du Toit et al., 2006). The in vitro drug release performance of our GluN-
LLA materials thus warrants future in vivo testing and motivated the cell uptake/ef-
ficacy studies presented in the paper.
3.6. Rifampicin release from submicron- and microparticles
As mentioned before, the most important concern in conventional TB treatment is
patient’s low compliance, which is primary based on its duration and intensity,
where the affected individual takes a significant number of pills daily for a long
time. In this case, a sustained release of RIF for a long period of time would greatly
reduce the administration frequency, and eventually increase patient’s adherence to
the treatment. Fig. 8 shows the cumulative RIF release curves from the four types of
particles. For all samples, two stages of RIF release can be identified; an initial one,
for up to 8 hours (Fig. 9, Step 1 and Fig. 8, insets), and a delayed phase, lasting from
8 to more than 300 hours (Fig. 9, Step 2 and Fig. 8). The SMP and MP prepared with
Fig. 8. Cumulative RIF release curves from submicron and microparticles. Release curves correspond to
SMP-GluN-LLA (:), MP-GluN-LLA () with RIF-to-polymer mass ratios of 1:10 and SMP-GluN-LLA
(D), MP-GluN-LLA (>), SMP-LLA and MP-LLA (star symbols) with RIF-to-polymer mass ratios of
1:5. Insets show the release profiles during the first 8 hours. Data represent means  SE (n ¼ 3).
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the GluN-LLA material as carrier yielded the desired results i.e., they were able to
keep more than 60% of RIF after an initial “burst release”, and thus to efficiently
release a dominant fraction of the drug over a period of two weeks. We attribute
this efficiency to molecular interactions between RIF and the polymeric matrix.
Linear polymers appeared to be less efficient than their branched counterparts in
yielding strong molecular interactions with the drug. SMP-LLA prepared using an
LMW PLA with a similar molecular weight to that of the GluN-LLA oligomer
(Table 1) allowed sustained drug release for 30e40 hours, and as much as 60% of
the drug was released within the first 8 hours. MP-LLA, on the other hand, showed
70% RIF release in the first 8 hours, followed by a sustained release over two weeks.
Similar results have been reported for PLGA (MW ¼ 5e15 kDa) SMP loaded with
budesonide (MW ¼ 430.5 Da) (Y.-H. Lee, Mei, Bai, Zhao and Chen, 2010), and for
RIF-loaded PLGA MP (Makino et al., 2004). Increasing particle sizes from 165 nm
to 289 nm extended the drug release time from 25-30 hours to 60 hours. Notably,
SMP (PDs: 169, 289 and 400 nm) prepared by these authors using a core-shell elec-
trospray approach (coaxial, two-liquid nozzle configuration) lost 40e60% of the
initial drug payload in just 5 hours. This was found to take place despite the protec-
tion provided by a shell made out of PLGA (100% drug encapsulation). We point to
the fact that these authors used the same drug release protocols we used in this paper,
which is obviously of utmost importance when comparing results from different
research groups.
There is little difference between the drug release kinetics from SMP and MP made
of GluN-LLA at 10 wt% and 20 wt% payloads (curves SMP-GluN-LLA (1:10) and
MP-GluN-LLA (1:5) in Fig. 8, respectively). The ability of our polymers to stabilize
high drug payloads is also a most desirable trait, and it suggests the occurrence of a
similar release mechanism for both particle diameter groups. This is consistent with
particle size-encapsulation efficiency relationships reported by others (Y.-H. Lee
et al., 2010).
Fig. 9. Representation of the bimodal kinetics of RIF release from the GluN-LLA carrier: 1) initial, 2)
delayed. In the delayed phase the drug passes through pores created by molecules released in the initial
phase (k1 > k2). In both phases the effects of drug-polymer interactions were evident and seen as
decreased values for the n exponent in the Korsmeyer-Peppas equation (Table 2).
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It is also apparent that the RIF release from SMP-LLA was mechanistically different
than that from the GluN-LLA materials. This could be attributed to their different
molecular architectures and chemical functionalities, since both polymers have
very similar MWs (Table 1). For LMW PLA, the drug release followed an anoma-
lous, non-Fickian diffusion model (n ¼ 0.71, Table 2) as defined by Ritger and Pep-
pas (0.43 < n < 1.00) (Ritger and Peppas, 1987). The Korsmeyer-Peppas equation
(see annotation c in Table 2 for details) predicts a diffusion-controlled drug release
mechanism for systems with diffusion exponent n¼ 0.43. All tested GluN-LLA sub-
micron- and microparticulate systems have much lower n-values (0.13e0.22, Table
2). This is indicative of drug-polymer matrix interactions, and these results are also
consistent with encapsulation efficiency tests and Differential Scanning Calorimetry
(DSC) results.
3.7. Particle toxicity on M. smegmatis
Chitosan, the polymeric form of glucosamine, has been regarded as having antimi-
crobial properties (Kong et al., 2010; Tikhonov et al., 2006) with its LMW kind
showing the higher bactericidal activity compared to its medium and HMW forms
(Melake, Mahmoud, & Al-semary, 2012). Also, the most accepted mechanism of
its antibacterial action is believed to involve the positive charge of the protonated
amine groups (Liu et al., 2004). For these reasons, we hypothesized a priori that
the presence of a glucosamine core (with free amine group, -NH2) in GluN-LLA
Fig. 10. Toxicity of particles on M. smegmatis. Mycobacteria were inoculated with different amounts of
submicron- and micron-sized particles and were cultured for 24 hours. 10 mL of culture was placed onto
agar plates and incubated at 37 C for three days to see visible colonies. Colony area was quantified from
pictures of agar plates using ImageJ software. Statistically significant differences between SMP-GluN-
LLA and MP-LLA (þp < 0.05); and between MP-GluN-LLA and MP-LLA (*p < 0.05) at a particle
concentration of 600 mg/mL, are shown. Statistically significant differences between MP-LLA and
MP-GluN-LLA, are indicative of promoted bacterial growth by the linear LLA when compared to the
branched GluN-LLA material (#p < 0.01). Data are presented as means  SE (n ¼ 3).
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(Skotak and Larsen, 2010) was possibly going to contribute some antibacterial ac-
tivity on M. smegmatis to the drug-carrier system, but as revealed in Fig. 10, this
was not the case. Fig. 10 shows the changes in % growth area compared to control
for SMP-GluN-LLA, MP-GluN-LLA, SMP-LLA and MP-LLA at 300, 600 and
1,200 mg of particles/mL. The observed trend was that changes in bactericidal activ-
ity for all particle types, and for all concentrations were not statistically different
from the control samples. However, there are statistically significant differences
among particle materials (MP-GluN-LLA vs MP-LLA, p < 0.01): while GluN-
LLA particles do not affect bacteria survival; MP-LLA seems to favorM. smegmatis
growth. This can be explained by the high correlation between microbial adhesion
and the hydrophobic/hydrophilic characteristics of the interacting surfaces. In this
regard, it has been shown that the adhesion of bacteria to solid surfaces is positively
affected by the surface’s hydrophobicity (Boks, Norde, van der Mei and Busscher,
2008; Katsikogianni and Missirlis, 2004). Oliveira et al. performed adhesion exper-
iments between different bacteria and polymeric surfaces. These authors found sur-
face hydrophobicity to be proportional to the number of adhering bacteria (Oliveira
et al., 2001). Thus, based on the observation that MP-LLA promotes bacterial
growth compared to MP-GluN-LLA, we can hypothesize that bacterial adhesion
to MP-LLA particles facilitated bacterial proliferation.
3.8. Minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) of free RIF and RIF loaded
particles
Table 3 summarizes the MIC and MBC results for free and encapsulated RIF. For
particles loaded at a 1:1 RIF-to-polymer mass ratio, SMP-GluN-LLA and MP-
GluN-LLA showed MIC values that were about half of that of free RIF on a same
dose of antibiotic basis. SMP-LLA showed MIC value 4 times lower than MIC value
of RIF alone, while MP-LLA showed MIC value similar to that of RIF alone. MBC
values were also affected by encapsulation: SMP-GluN-LLA and SMP-LLA showed
Table 3. MIC and MBC values of RIF in both free and encapsulated form were
determined by the macrobroth dilution technique. Particles were produced with a
1:1 RIF-to-polymer mass ratio.
MIC (1:1) (mg/mL) MBC (1:1) (mg/mL)
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MBC values 2 times lower than free RIF, while MBC values for MP-LLA and MP-
GluN-LLA were unaffected.
Improved efficacy of antibiotics encapsulated in liposomes and intracellular delivery
of antibiotics on different microbial strains has been reported. Mirzaee et al. (Mirzaee
et al., 2009) have found decreased values of MIC for encapsulated amikacin
compared to free amikacin for E. coli, P. aeruginosa, S. faecalis and S. aureus. In
the same manner, when liposomes were used as encapsulants for amikacin, genta-
micin and tobramycin, they reduced the MICs for highly antibiotics-resistant strains,
while improving the uptake of antibiotics into the bacterial cells (Halwani et al.,
2007). One possible explanation for this phenomenon is membrane fusion between
liposomes and bacteria. This would deliver a high dose of antibiotic to the microor-
ganism, and therefore surpass the bacteria efflux pump capacity (Sachetelli et al.,
2000; L. Zhang, Pornpattananangku, Hu and Huang, 2010). Another example where
the bactericidal effect was also enhanced was shown by the use of RIF-loaded MP.
PLGA MP loaded with RIF showed a greater bactericidal effect on Mycobacterium
bovis Bacillus Calmette-Guerin (BCG) in AM cells than that of RIF in solution when
compared at the same periods of time (Hirota et al., 2010). Similar results were ob-
tained by Makino and coworkers (Makino et al., 2004), but in this case higher
amounts of RIF were detected inside AM cells treated with RIF-loaded MP than
when treated with RIF alone.
MIC reduction in RIF-loaded GluN-LLA and SMP-LLA particles indicates an in-
crease in bacterial killing relative to free RIF. Our tests indicate that antibacterial
Fig. 11. Particle induced cytotoxicity on macrophages. Different concentrations of GluN-LLA and LLA
submicron and microparticles were incubated with macrophages for 3 days. The WST-8 reagent solution
was contacted with the samples for one hour prior to OD450 measurement with a BioTek Elx800 micro-
plate reader. Cytotoxicity of submicron and microparticles increased with increasing particle doses. All
particle types’ cytotoxicity effects were statistically significant in terms of particle concentration when
compared to their controls (*p < 0.05). Data represent means  SE (n ¼ 4).
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properties of drug-free GluN-LLA and PLA particles onM. smegmatis are negligible
(Fig. 10). Thus, RIF encapsulation must facilitate endocytosis, resulting in a locally
elevated antibiotic concentration.
3.9. Cytotoxicity of particles on macrophage cells
1 In order to determine the cytotoxicity of the four sets of particles, the WST-8
viability assay was implemented. Fig. 11 shows the survival rate (%) of macrophages
after three days of incubation with the drug-free (no RIF) particles. Cytotoxicity was
shown to be dose dependent i.e., at increasing particle doses there was an increase in
cell death. Cytotoxicity was not significantly affected by the material type; at one
specific dose level, all particle types showed a very similar effect. When comparing
particle concentrations with the control, all particle types showed statistically signif-
icant differences at 120 and 240 mg/ml. At a concentration of 60 mg/ml, only SMP-
GluN-LLA particles showed significantly different cytotoxicity levels in macro-
phages relative to the controls. The clear inhibition in macrophages proliferation
that occurs at a particle concentration of 120 mg/ml, and at higher values can be
due to an accumulation of free lactic acid in the culture media. As a product of poly-
mer degradation, lactic acid could cause a localized, lethal decrease in pH. This has
been previously proposed to explain the cytotoxic effect observed with LLA grafted
chitosan (Skotak et al., 2008). The cytotoxicity of SMP-GluN-LLA particles at 60
mg/ml (w20%), could be also correlated with their high cellular uptake (shown in
Fig. 12) due to smaller particle size. The increasing number of particles undergoing
Fig. 12. Internalization of particle by macrophages. Submicron- and micron-sized particles made from
GluN-LLA and LLA labeled with PCL-fluorescein were incubated with macrophages. Cells were washed
and analyzed with confocal microscopy. The fluorescence intensity/cell of the different types of particles
was quantified by ImageJ software. Macrophages showed statistically significant higher SMP and MP
uptake made with the branched GluN-LLA polymer than the particles made with the linear LLA poly-
mer. Statistically significant differences (**p < 0.01), and statistically significant differences when
comparing with all populations (þþp < 0.01) are seen. Data represents means  SE (n ¼ 4).
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endocytosis can lead to an increment in the production of reactive oxygen species
(ROS), which is linked to toxicological effects (Nel et al., 2006).
3.10. Particle uptake and intracellular localization
Particle internalization into J774 macrophages was determined by incubation of
plasma membrane stained cells with fluorescein-labelled RIF-free particles for 48
hours. Fig. 12 depicts the fluorescence intensity/cell quantified in confocal micro-
scopy images for different types of particles. As noted, macrophages displayed
higher internalization of GluN-LLA than PLA particles, with the SMP-GluN-LLA
type showing the highest uptake. Particle properties such as hydrophobicity, size,
shape, and surface charge affect the cellular uptake (Fr€ohlich, 2012). Since particle
size is similar for the SMP and MP materials (Table 1), the differences between
GluN-LLA and PLA could in principle be related to surface properties (charge
and hydrophobicity).
To determine the actual location of particles inside cells, confocal microscopy was
employed; using optical sectioning technique on macrophages having blue plasma
membrane and red lysosome (Fig. 13A), and red mitochondria staining
(Fig. 13B), respectively. In these images, stained particles (green) revealed that par-
ticles did not colocalize in mitochondria or lysosomes, and after internalization, they
remained in the cytoplasm. What we found is of critical relevance to the proposed
medical application: the absence of mitochondrial colocalization of particles is
extremely desirable. If macrophage targeting is intended, particle colocalization in
this organelle is expected to promote oxidative stresses that could lead to cell death.
Our results described in the previous sub-section indicate that particle cytotoxicity
on macrophages is directly related to particle dose (Fig. 11). However, according
to results presented in Fig. 13 particle colocalization cannot be the culprit of these
cytotoxic effects. Previous studies showed that PLGA MP loaded with RIF colocal-
ize in phago-lysosomes (Onoshita et al., 2010) suggesting that released RIF mole-
cules diffuse first through the membrane of the phagosomes containing particles
to the cytoplasm and then, also by diffusion, enter the phagosomes containing the
bacteria. Contrary to this two-step gradient diffusion, a sustained release of RIF
directly into the cytoplasm from GluN-LLA particles produces a strong concentra-
tion gradient within phago-lysosomes containing bacteria (one step diffusion).
Therefore, RIF diffusion through the bacterial membrane and intracellular killing
is highly improved. What is also of key relevance to the goals of this study is that
GluN-LLA particles showed higher uptakes by macrophages compared to those
made of HMW PLA. This property can obviously be very desirable when consid-
ering the design of a macrophage-targeting drug delivery system (a K. Agrawal
and Gupta, 2000; Terada and Hirota, 2012). Thus, our results demonstrate these
polymers meet two important requirements for anti-TB drug delivery applications,
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namely: a) high macrophage uptakes and b) dose-dependent, but overall low
cytotoxicity.
3.11. Intracellular killing of M. smegmatis
2 In order to evaluate the in vitro mycobactericidal effect of RIF-loaded GluN-LLA
and PLA particles on M. smegmatis inside phagosomes, macrophages were first
exposed to a very high MOI of 20 to facilitate infection, and after washing away
the extracellular microorganism fraction, infected cells were contacted with RIF
loaded particles. Free RIF and no-treatment samples were included in this experi-
ment. The intracellular killing effectiveness of free and encapsulated RIF was deter-
mined by the ratio between the number of intracellular bacteria (c.f.u.) and the
number of cells alive at the same time point (Fig. 14). The results of no-treatment
control experiment are presented as inset in Fig. 14, shows the typical and previously
observed cyclical behavior of killing/growth of M. smegmatis inside J774A.1 mac-
rophages (Anes et al., 2006; Sonawane et al., 2011). Anes and co-workers observed
this cyclic interplay between death and regrowth of M. smegmatis bacteria in cul-
tures with MOI values of 5e10, and within 48 hours macrophages managed to suc-
cessfully eliminate all intracellular bacteria. In order to test the killing efficiency of
our sustained release RIF preparations for prolonged period of time (10 days), a very
high MOI of 20 was used. Note that in the case of a pathogenic mycobacterium like
MTB, such high level of infection would naturally cause macrophage apoptosis. Lee
and colleagues determined thatMTB rapidly induces cell apoptosis (90% cells die in
merely 20 hours) for MOI> 10. Also, these authors demonstrated thatM. Smegmatis
had a minimal effect on macrophage death at MOI 25 and 50 (J. Lee, Remold, Ieong
and Kornfeld, 2006), a characteristic treat that granted long-term infection.
3 We evaluated the antibacterial performance of RIF-loaded particulate systems, and
compared it with free RIF for 10 days, using a RIF amount corresponding to half
MIC value (Table 3). Free RIF is very effective in killing intracellular bacteria during
initial 4 days, as shown by relatively low c.f.u/cell numbers for that period of time
(Fig. 14). After day 3, a cyclic pattern is apparent, indicating a reduction in RIF
effectiveness. In the case of encapsulated RIF, all systems showed an oscillatory
behavior, with a significant reduction in c.f.u/cell values when compared to the con-
trol. All tested particulate systems appear to be more efficient in killing bacteria after
day 5. This is an expected outcome, and can be explained by the decreased bioavail-
ability of free RIF in culture media at 37 C, where as much as 50% of the drug is
degraded in one week (Yu et al., 2010), while the encapsulated form is protected
against these adverse degradation processes. The number of intracellular bacteria
per cell in GluN-LLA and PLA polymers seems to be related to the RIF release
mechanism (Fig. 8). Both GluN-LLA and SMP-LLA systems presented higher num-
ber of intracellular bacteria per cell than free RIF during the first 4 days, but superior
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Fig. 13. Intracellular localization of particles. Mitochondria and Lysosome were stained with mitotracker
and lysotracker, respectively. In order to be visualized particles containing PCL fluorescein were pro-
duced. Part A shows the images of lysosome stained cells: cytoplasm membrane staining (blue) and lyso-
some staining (red) after incubation with fluorescein loaded particles (green). Part B shows the images of
mitochondria stained cells: mitochondria staining (red) after incubation with fluorescein loaded particles
(green). Particles are engulfed by the cells, but they do not colocalize either with mitochondria or with
lysosomes i.e., they stay in the cytoplasm. The scale bar is 20 mm for all images.
26 https://doi.org/10.1016/j.heliyon.2019.e01539




Fig. 14. Intracellular killing of M. smegmatis. Macrophages were infected with M. smegmatis at an MOI
of 1:20 (cells:bacteria). After infection macrophages were contacted with free RIF, and or RIF loaded
particles. Inset shows control experiments where M. smegmatis showed a cyclic growth/killing pattern
of colony forming units of intracellular M. smegmatis per macrophage cell in terms of time.
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killing efficiencies after day 6. On the other hand, the MP-PLA polymer showed a
different behavior: similarly, to free RIF, the bioactivity, seen as low c.f.u. per
cell numbers, is strongly enhanced during the initial 6 days, which can be attributed
to the high burst release of the drug that is characteristic of this system (Fig. 8,
w70% of the drug is released in 8 hours). Our studies demonstrate that careful
tailoring of the physicochemical properties of polymeric particles, even these
ones, prepared using the same monomer but differing in molecular architecture
will allow the design of a delivery system whose drug release profile can be engi-
neered virtually at will.
4 It is worth mentioning that after a thorough literature search, studies assessing
effectiveness of RIF-loaded particles in macrophages infected with M. smegmatis
(as a safe laboratory model to study TB therapeutic strategies) and spanning for
more than one day were not found. As one relevant (albeit indirect) example, Sona-
wane and colleagues (Jena et al., 2012; Mohanty et al., 2013; Sonawane et al., 2011)
performed evaluation of antimicrobial properties of several types of starch- and
chitosan-coated silver nanoparticles using mouse macrophages infected with M.
smegmatis (MOI ¼ 10). The study presented in this manuscript seems to have
offered, for the first time, results on the long-term (drug release over several days)
performance of RIF-loaded ultrafine particles on M. smegmatis internalized in mac-
rophages as an arguably more realistic TB model.
4. Conclusion
Using a new biocompatible polymer system based on glucosamine and L-lactide, we
have prepared RIF-loaded submicron- and micron-sized particles via an EHDA
route. A nearly linear sustained RIF release profile was observed for up to 14
days in vitro for GluN-LLA particles. Enhanced RIF-matrix interactions were sup-
ported by Korsmeyer-Peppas equation data fitting results, DSC and drug encapsula-
tion efficiency evaluated via ethanol leaching. Four terminal -OH groups and one
primary eNH2 group are present in GluN-LLA molecules, as opposed to just a sin-
gle terminal eOH moiety in the linear PLA. Increased hydroxyl groups density in
these polymers is expected to promote matrix-drug interactions via hydrogen
bonding. Thus, molecular affinity seemed to have been the dominant release mech-
anism in our case. Polymers that show high macrophage internalization without co-
localization into different organelles are excellent candidates for the production of
anti-TB drug carrier particles. This was the case with GluN-LLA based polymers:
the drug-loaded particles remain in the cytoplasm, releasing RIF in close proximity
to intracellular bacteria. Intracellular killing of M. smegmatis by different particles
showed a cyclic interplay between live and dead bacteria. The presence of free or
encapsulated RIF at sub-MIC concentrations was effective in reducing the number
of bacteria per cell compared to the control. It is suggested that the combination
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of different particle types and sizes involving at least one type of particle made from
the new polymers used in this study will ultimately lead to the design of a system
with optimal drug release profiles. Our overarching goal was to design a drug deliv-
ery system capable of attacking the microorganism over a long period of time and
with just one dose. For a given set of chemical characteristics that could lead to
carrier-drug interactions, polymeric materials with higher branching point densities
and with amorphous structures may in principle extend RIF release times. The
in vitro results presented in this paper indicate that GluN-LLA polymeric systems
are promising candidates for this particular application.
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